Business Context and Reporting Period
This Form 8-K is filed by KBL Merger Corp. IV (KBL), a Delaware special purpose acquisition company (SPAC), on May 14, 2019. The filing discloses the execution of a non-binding term sheet for a proposed business combination with CannBioRx Life Sciences Corp. and its subsidiaries (collectively, the "CannBioRx Parties"). KBL trades on the NASDAQ under the symbols KBLM (Common Stock), KBLMW (Warrants), KBLMR (Rights), and KBLMU (Units).
Key Financial Metrics and Transaction Terms
- Transaction Valuation: The proposed acquisition of 100% of CannBioRx equity is valued at $175 million, subject to adjustments for indebtedness and cash at closing.
- Consideration Structure: KBL will issue common stock ("Transaction Shares") valued at the redemption price payable to public stockholders.
- Liquidity Requirement: The parties agreed to ensure at least $40 million in cash is available at closing via backstop commitments or financing.
- Working Capital Loans: CannBioRx Parties deposited $400,000 in escrow as an interest-free, unsecured loan for operating and transaction expenses. An additional $300,000 may be deposited for potential extension expenses.
- Debt and Cash Adjustments: The $175 million valuation will be reduced by CannBioRx indebtedness and increased by CannBioRx cash as of the closing date.
Material Changes and Transaction Status
The filing represents a material development in KBL's search for an initial business combination. While a term sheet was previously disclosed on April 16, 2019, this filing details the specific valuation and financial mechanics. The transaction is currently non-binding and contingent upon the execution of a definitive agreement. A corporate restructuring of CannBioRx and its subsidiaries is planned prior to or simultaneously with the closing.
Guidance, Risks, and Contingencies
- Exclusivity Period: KBL and CannBioRx agreed to an exclusivity period until June 10, 2019, during which neither party may solicit alternative transactions. This period can be terminated early if negotiations are abandoned or not conducted in good faith.
- Verification: The $175 million valuation must be verified by an investment bank acceptable to all parties before a definitive agreement is signed.
- Risks: The filing highlights significant risks, including the failure to enter a definitive agreement, inability to meet NASDAQ listing standards post-transaction, insufficient cash following stockholder redemptions, and regulatory or litigation challenges regarding CannBioRx's intellectual property.
- Forward-Looking Statements: Management cautions that the transaction may not be consummated and that actual results may differ materially from expectations.
Investor Verification Checklist
- Verify the final valuation of CannBioRx after the investment bank verification process.
- Confirm the status of the $40 million cash requirement and the identity of any backstop providers.
- Monitor the execution of the definitive agreement and the terms of the corporate restructuring.
- Review the upcoming proxy statement/prospectus for details on stockholder redemption rights and voting procedures.
- Assess the impact of potential stockholder redemptions on the post-transaction cash balance.